FTC Urged To Investigate AbbVie’s IP Strategy On Humira
US Representatives Suggest Biosimilar Adalimumab Competition Delayed From 2017 To 2023
AbbVie delayed biosimilar competition to Humira “for far longer than warranted” and may have “engaged in other anti-competitive conduct to maintain its market share and pricing power” for the adalimumab brand, according to members of the US House of Representatives’ committee on oversight and reform. The US Federal Trade Commission has been urged to open a formal inquiry into the originator’s conduct.
